Good News for Humankind

Your daily spark of possibility

The world is changing — for the better, and in real, indisputable ways. Climate breakthroughs. Justice wins. Scientific discoveries. From people you’ve never heard of. In places you wouldn’t expect.

Every weekday, I send a piece of good news from around the world — not to sugarcoat reality, but to remind you that change is possible.

Every weekday morning at 7am. Or sign up for the weekly digest.

What Readers Are Saying

It restores my faith that homo sapiens sapiens, even if not in everything and always, deserves the name it has given itself.

Eszter

Peter is all passion. He’s spent years working toward the greater good by helping his readership and community becoming the best version of themselves. His thoughtfully curated positive news stories stem from his genuine and effortless capacity to empathize. You’re an inspiration, Peter. Thank you!

Athos Cakiades Company Name

Good News daily restores my faith in humanity and in Universal Source; I’ve shared this newsletter with family and friends and we love it! Hurray for Peter’s inspiration and generosity! So grateful.

Eve Thompson Company Name

I forward this to friends who need a remedy for despair.

Alice PrestonCompany Name

Good News for Humankind has been a crack of light in my inbox for years
because it provides a some counter balance to the dystopian info-tsunami
that passes for news from other sources.

Tim TaylorCompany Name

The Latest Good News

Search

Topic

Country

Actor

A researcher handling a vaccine vial in a clinical lab for an article about cancer vaccine trials, for article on cancer chemotherapy, for article on personalized cancer vaccine

2024 C.E. May 31

NHS launches world-first cancer vaccine matchmaking program in England

Cancer vaccine trials are now being fast-tracked through a landmark NHS program in England that matches patients with personalized mRNA vaccines built around their individual tumors. The Cancer Vaccine Launch Pad, operating across 30 hospitals, uses the same mRNA technology behind COVID-19 vaccines to design custom treatments targeting each patient's unique cancer mutations. The program aims to eliminate remaining cancer cells after surgery before they can return. Early immune response data is encouraging, and...

Karla Sofia Gascon, for article on Cannes Film Festival history

2024 C.E. May 30

Karla Sofía Gascón becomes the first trans woman to win award for Best Actress at Cannes

Karla Sofía Gascón became the first openly transgender woman to win Best Actress at Cannes, sharing the 2024 honor with her three Emilia Pérez co-stars in a collective award chosen by Greta Gerwig's jury. Gascón plays a Mexican drug lord who transitions in Jacques Audiard's genre-bending musical, which also took home the festival's Jury Prize. In her speech, she dedicated the win to "all trans people who suffer so much and must keep faith...

Aral Sea time lapse 1989 2014, for article on Aral Sea afforestation

2024 C.E. May 30

Uzbekistan plants millions of acres of forest where the Aral Sea once lay

Aral Sea afforestation has covered 1.7 million hectares of dried lakebed with saxaul trees and other desert-tolerant plants over the past five years, transforming what was once the world's fourth-largest lake into a slowly recovering landscape. The work is led on the ground by Karakalpak communities, where women gather seeds each autumn and men join planting crews through the winter. A single mature saxaul shrub can hold back several tons of moving sand, shielding...

A neuron or nerve cell is an electrically excitable cell, for article on ALS synapse-regenerating pill

2024 C.E. May 29

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

A once-daily ALS pill designed to rebuild neural connections — not just slow their loss — has cleared FDA approval to begin Phase 2 trials, with patients across the U.S. starting doses in April 2024. SPG302 works on synapses, the tiny junctions where neurons talk to each other, which start vanishing before motor neurons themselves die. Every ALS drug currently on the market aims to slow decline; this one is being tested for whether...

Good news for public health, for article on CAB-LA HIV prevention, for article on lenacapavir HIV prevention, for article on HIV infections in young men

2024 C.E. May 23

HIV transmissions in the U.S. dropped 12% between 2018 and 2002

HIV infections among young men in the U.S. dropped 30% between 2018 and 2022, the steepest decline of any age group in the latest CDC surveillance data. Researchers credit expanded testing, faster connection to treatment, and the growing reach of PrEP — a daily pill that cuts transmission risk by up to 99% when taken consistently. The South, long carrying the heaviest HIV burden in the country, saw the largest regional drop, and Black...

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160

Enjoying these stories? Get one delivered to your inbox every weekday morning — free.

Go to good news archives for specific countries, institutions, topics, etc.